1 research outputs found
Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
The Cancer Genome Atlas (TCGA) has classified papillary thyroid carcinoma (PTC) into
indolent RAS-like and aggressive BRAF-like based on its distinct driver gene mutations. This retro-
spective study aimed to assess clinicopathology and pERK1/2 expression variations between BRAF-
like and RAS-like PTCs and establish predictive models for BRAFV600E and RAS-mutated PTCs. A
total of 222 PTCs underwent immunohistochemistry staining to assess pERK1/2 expression and
Sanger sequencing to analyze the BRAF and RAS genes. Multivariate logistic regression was em-
ployed to develop prediction models. Independent predictors of the BRAFV600E mutation include
a nuclear score of 3, the absence of capsules, an aggressive histology subtype, and pERK1/2 levels
exceeding 10% (X 2 = 0.128, p > 0.05, AUC = 0.734, p < 0.001). The RAS mutation predictive model
includes follicular histology subtype and pERK1/2 expression >10% (X 2 = 0.174, p > 0.05, AUC = 0.8,
p < 0.001). We propose using the prediction model concurrently with four potential combination
group outcomes. PTC cases included in a combination of the low-BRAFV600E-scoring group and
high-RAS-scoring group are categorized as RAS-like (adjOR = 4.857, p = 0.01, 95% CI = 1.470–16.049).
PTCs included in a combination of the high-BRAFV600E-scoring group and low-RAS-scoring group
are categorized as BRAF-like PTCs (adjOR = 3.091, p = 0.001, 95% CI = 1.594–5.995). The different
prediction models indicate variations in biological behavior between BRAF-like and RAS-like PTCs. Keywords: papillary thyroid carcinoma; BRAF-like; RAS-like; BRAFV600E; RAS mutation;
prediction mode